Xiaojie Cai

Xiaojie Cai

Auto-generated profile, based on publicly available information

Xiaojie Cai

Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
XCXiaojie Cai
Xiaojie Cai
MHMaoying Han
Maoying Han
FLFangzhou Lou
Fangzhou Lou
YSYang Sun
Yang Sun
QYQianqian Yin
Qianqian Yin
HWHonglin Wang
Honglin Wang
Dermal fibroblasts and cutaneous nerves are important players in skin diseases, while their reciprocal roles during skin inflammation have not been characterized. Here we identify an inflammation-induced subset of papillary fibroblasts that promotes aberrant neurite outgrowth and psoriasiform skin inflammation by secreting the extracellular matrix protein tenascin-C (TNC). Single-cell analysis of fibroblast lineages reveals aTnc+papillary fibroblast subset with pro-axonogenesis and neuro-regulation transcriptomic hallmarks. TNC overexpression in fibroblasts boosts neurite outgrowth in co-cultured neurons, while fibroblast-specific TNC ablation suppresses hyperinnervation and alleviates skin inflammation in male mice modeling psoriasis. Dermal γδT cells, the main producers of type 17 pathogenic cytokines, frequently contact nerve fibers in mouse psoriasiform lesions and are likely modulated by postsynaptic signals. Overall, our results highlight the role of an inflammation-responsive fibroblast subset in facilitating neuro-immune synapse formation and suggest potential avenues for future therapeutic research.

12 January 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
QYQianqian Yin
Qianqian Yin
LSLibo Sun
Libo Sun
XCXiaojie Cai
Xiaojie Cai
FLFangzhou Lou
Fangzhou Lou
YSYang Sun
Yang Sun
HWHonglin Wang
Honglin Wang

30 January 2024 in EMBO Reports
Verified
Journal Article
Open access
STSibei Tang
Sibei Tang
JZJunxun Zhang
Junxun Zhang
FLFangzhou Lou
Fangzhou Lou
HZHong Zhou
Hong Zhou
XCXiaojie Cai
Xiaojie Cai
HWHonglin Wang
Honglin Wang
Micropeptides encoded by short open reading frames (sORFs) within long noncoding RNAs (lncRNAs) are beginning to be discovered and characterized as regulators of biological and pathological processes. Here, we find that lncRNA Dleu2 encodes a 17-amino-acid micropeptide, which we name Dleu2-17aa, that is abundantly expressed in T cells. Dleu2-17aa promotes inducible regulatory T (iTreg) cell generation by interacting with SMAD Family Member 3 (Smad3) and enhancing its binding to the Foxp3 conserved non-coding DNA sequence 1 (CNS1) region. Importantly, the genetic deletion of Dleu2-17aa in mice by start codon mutation impairs iTreg generation and worsens experimental autoimmune encephalomyelitis (EAE). Conversely, the exogenous supplementation of Dleu2-17aa relieves EAE. Our findings demonstrate an indispensable role of Dleu2-17aa in maintaining immune homeostasis and suggest therapeutic applications for this peptide in treating autoimmune diseases.

29 October 2025 in Nature Aging
Verified
Journal Article
Closed access
PDF file
MGMin Gao
Min Gao
JBJing Bai
Jing Bai
FLFangzhou Lou
Fangzhou Lou
YSYang Sun
Yang Sun
ZWZhikai Wang
Zhikai Wang
HWHonglin Wang
Honglin Wang

15 August 2025 in Nature Communications
Verified
Journal Article
Open access
YSYang Sun
Yang Sun
FLFangzhou Lou
Fangzhou Lou
XCXiaojie Cai
Xiaojie Cai
ZWZhikai Wang
Zhikai Wang
XYXiuli Yang
Xiuli Yang
HWHonglin Wang
Honglin Wang
Interleukin (IL)-23 is the master pathogenic cytokine in psoriasis and neutralization of IL-23 alleviates psoriasis. Psoriasis relapses after the withdrawal of anti-IL-23 antibodies, and the persistence of IL-23-producing cells potentially contributes to such recurrence, but the cellular source of IL-23 is unclear. Here we show that IL4I1+CD200+CCR7+ dendritic cells (CCR7+ DC) are the main producer of IL-23 by concomitantly expressing the IL-23A and IL-12B subunits in human psoriatic skin. Deletion of CCR7+ DC completely abrogates IL-23 production in a mouse model of psoriasis, while enforced expression of IL-23a in CCR7+ DC elicits not only αβT cell-driven psoriasis-like skin disease, but also arthritis. CCR7+ DC co-localize with CD161+ IL-17-producing T cells and KRT17+ keratinocytes, which are located in the outermost layers of psoriatic epidermis and exhibit IL-17 downstream signatures. Our data thus identify CCR7+ DC as the source of IL-23 in psoriasis, and paves the way for IL-23-targeting therapy for suppressing the relapse of chronic inflammatory disorders like psoriasis.

10 June 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
XLXiangxiao Li
Xiangxiao Li
FZFengjiao Zhang
Fengjiao Zhang
LSLibo Sun
Libo Sun
XCXiaojie Cai
Xiaojie Cai
FLFangzhou Lou
Fangzhou Lou
HWHonglin Wang
Honglin Wang
Psoriasis is a common inflammatory skin disorder with no cure. Mesenchymal stem cells (MSCs) have immunomodulatory properties for psoriasis, but the therapeutic efficacies varied, and the molecular mechanisms were unknown. In this study, we improved the efficacy by enhancing the immunomodulatory effects of umbilical cord–derived MSCs (UC-MSCs). UC-MSCs stimulated by TNF-α and IFN-γ exhibited a better therapeutic effect in a mouse model of psoriasis. Single-cell RNA sequencing revealed that the stimulated UC-MSCs overrepresented a subpopulation expressing high tryptophanyl-tRNA synthetase 1 (WARS1). WARS1-overexpressed UC-MSCs treat psoriasis-like skin inflammation more efficiently than control UC-MSCs by restraining the proinflammatory macrophages. Mechanistically, WARS1 maintained a RhoA-Akt axis and governed the immunomodulatory properties of UC-MSCs. Together, we identify WARS1 as a master regulator of UC-MSCs with enhanced immunomodulatory capacities, which paves the way for the directed modification of UC-MSCs for escalated therapeutic efficacy.